Oslo, Norway-based Zelluna Immunotherapy is partnering with the Swedish Karolinska Institutet (KI) to develop next generation novel immuno-oncology products for the treatment of solid cancers.
Zelluna is focused on the use of T cell receptor (TCR) guided Natural Killer (NK) cell therapy products for the treatment of solid cancers.
The collaboration will support a multi-year research program aimed at developing next generation TCR guided NK cells, making use of Zelluna’s proprietary TCR-NK technology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze